Related Experiment Video
Updated: Sep 26, 2025
06:28
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
8.4K
Inflammatory Bowel Disease Patients' Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT
Stefan Schubert1, Nils Picker2, Taner Cavlar3
1Gastroenterology Practice am Bayerischen Platz, Innsbrucker Str. 58, 10825, Berlin, Germany.
Advances in Therapy
|April 22, 2022
Summary
Patients with Crohn's disease (CD) and ulcerative colitis (UC) prioritize treatment efficacy and safety. Understanding these preferences for advanced therapies can enhance treatment effectiveness for moderate to severe inflammatory bowel disease.
Area of Science:
- Gastroenterology and Hepatology
- Health Services Research
- Patient-Reported Outcomes
Background:
- The treatment landscape for Crohn's disease (CD) and ulcerative colitis (UC) is rapidly evolving with new advanced therapies.
- Understanding patient preferences is crucial for optimizing treatment selection and improving therapeutic outcomes in inflammatory bowel disease (IBD).
- Discrete choice experiments (DCEs) are valuable tools for quantifying patient preferences for complex healthcare decisions.
Purpose of the Study:
- To investigate patient preferences for key attributes of advanced therapies in Crohn's disease (CD) and ulcerative colitis (UC).
- To determine the relative importance of efficacy, safety, and administration-related factors in patient treatment choices for IBD.
- To inform clinical decision-making and treatment guideline development by incorporating patient-centered values.
Main Methods:
- A discrete choice experiment (DCE) was conducted with adult patients diagnosed with CD or UC.
- Patients evaluated hypothetical treatment alternatives based on attributes such as remission rates, adverse event profiles, and administration mode.
- A conditional logit model was employed to estimate the relative importance of each treatment attribute based on patient choices.
Main Results:
- For Crohn's disease (CD), 1-year remission rate (42.3%) was the most critical attribute, followed by serious adverse events (25.1%) and sustained remission (17.8%).
- For ulcerative colitis (UC), efficacy outcomes (mucosal healing 25.3%, corticosteroid-free remission 23.4%) and serious adverse events (18.3%) were paramount.
- Administration mode and non-serious adverse events also influenced patient decisions, with varying importance between CD and UC patients.
Conclusions:
- Efficacy and safety (specifically serious adverse events) are the primary drivers of treatment preferences for both CD and UC patients.
- Patient preferences for non-serious adverse events and long-term sustained remission differ between CD and UC.
- Incorporating patient-centered preferences into treatment selection can enhance the effectiveness of therapies for moderate to severe CD and UC.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
439
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
439
01:29Inflammatory Bowel Disease IV: Pharmacological Management
215
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
215
01:21Inflammatory Bowel Disease V: Surgical Management
239
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
239
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
226
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
226
01:17Drugs for Treatment of Diarrhea-Predominant IBS
332
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
332
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282